報價延遲最少15分鐘:2026/03/28 19:05 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
72.82 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
3.32/9.69
|
|
企業價值
2.26B
|
| 資產負債 |
|
每股賬面淨值
24.12
|
| 現金流量 |
|
現金流量率
0.12
|
| 損益表 |
|
收益
883.37M
|
|
每股收益
20.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology,rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically,it generates maximum revenue from the United States, followed by other markets. |
